NEI Research News

A form of gene therapy protects optic nerve cells and preserves vision in mouse models of glaucoma, according to research supported by NIH’s National Eye Institute. The findings suggest a way forward for developing neuroprotective therapies for glaucoma.

Consuming large amounts of daily caffeine may increase the risk of glaucoma more than three-fold for those with a genetic predisposition to higher eye pressure according to an international, multi-center study.

A new combination of optical coherence tomography (OCT), adaptive optics and deep neural networks should enable better diagnosis and monitoring for neuron-damaging eye and brain diseases like glaucoma.

More than 20 years after the launch of a landmark clinical trial, follow-up examinations and analyses found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma.

A new study showed that ingesting the compound citicoline restored optic nerve (neural) signals between the brain and eye to near-normal levels in the study rats.

Researchers for the first time analyzed genes in more than 34,000 people with glaucoma across multiple ancestries and found 44 new genetic variants that may lead to new treatment targets.

In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged by blinding diseases.

Research from the Stowers Institute suggests that the ciliary body might be key to detecting eye diseases before vision is impaired.

Children who undergo cataract surgery as infants have a 22% risk of glaucoma 10 years later, whether or not they receive an intraocular lens implant. The findings come from the National Eye Institute (NEI)-funded Infant Aphakic Treatment Study.

Researchers at Georgia Tech have developed a potential new treatment for the eye disease glaucoma that could replace daily eyedrops and surgery with a twice-a-year injection to control the buildup of pressure in the eye.